RESEARCH USE ONLY. UK DISPATCH. ≥98% PURITY. SAME DAY DISPATCH BEFORE 2 PM MON–FRI. NOT FOR HUMAN CONSUMPTION
Lynx Peptides
Basket 0

Human clinical evidence

SS-31 research overview

Review the published research context, areas studied and evidence limitations associated with this catalogue material.

Evidence context statedSources linkedLast reviewed

Research context

SS-31 is identified in clinical literature as elamipretide, a mitochondria-targeting peptide studied in controlled trials of primary mitochondrial myopathy and related mitochondrial disorders.

Areas studied

  • Mitochondrial membrane research
  • Exercise-performance endpoints
  • Fatigue measures
  • Primary mitochondrial myopathy

Limitations and investigational status

Small early studies produced exploratory signals, but a larger phase 3 trial did not meet its primary exercise or fatigue endpoints. The evidence therefore remains condition-specific and mixed.

References

  1. 1Karaa et al. - Journal of Cachexia, Sarcopenia and Muscle, 2020
  2. 2Karaa et al. - Neurology, 2023

For laboratory research use only. Information presented here summarises areas investigated in published research and is not intended as medical advice or as evidence of established effects in humans.